<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[디어젠 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=37448></link><description><![CDATA[디어젠 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Thu, 09 Apr 2026 06:24:14 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2021/04/12_3554238800_20210413085502_7922250612.png]]></url></image><language>ko-KR</language><item><title><![CDATA[디어젠, 독일 DEL 기업 ‘세렌젠’과 공동 서비스 파트너십 체결]]></title><link>https://www.newswire.co.kr/newsRead.php?no=971126</link><description><![CDATA[서울--(뉴스와이어)--인공지능(AI) 기반 파마테크(Pharmatech) 기업 디어젠(CEO 강길수)이 독일의 유전자 암호화 라이브러리(DNA-Encoded Library, 이하 DEL) 기업 세렌젠과 공동 서비스 파트너십을 체결했다고 25일 밝혔다.   세렌젠은 독일의 DEL 전문기업으로, 신약 개발에 필요한 유효 물질을 빠르게 접근·발견할 수 있도록 하는 기술을 보유하고 있다. 이 기술은 기존 DEL 합성의 한계를 극...]]></description><image><url><![CDATA[https://file.newswire.co.kr/data/datafile2/thumb/2023/07/1028147215_20230724161252_1714217604.jpg]]></url></image><pubDate>Tue, 25 Jul 2023 09:00:00 +0900</pubDate></item><item><title><![CDATA[Deargen Signs Agreement With Sookmyung Women’s University Research & Business Development Foundation for Licensing NASH Biomarker Technologies]]></title><link>https://www.newswire.co.kr/newsRead.php?no=927807</link><description><![CDATA[SEOUL--(Korea Newswire)--Deargen (President: Kilsoo Kang), an artificial intelligence (AI)-powered drug discovery and development company, announced that it has signed an agreement with Sookmyung Women’s University Research &amp; Business Development Foundation for licensing biomarker technologies for determining the progression stage of NASH (non-alcoholic steatohepati...]]></description><image><url><![CDATA[https://file.newswire.co.kr/data/datafile2/thumb/2021/07/3554238800_20210728094429_8927442849.jpg]]></url></image><pubDate>Wed, 28 Jul 2021 09:49:38 +0900</pubDate></item><item><title><![CDATA[Deargen Announces New Model of Optimizing Drug Candidate Molecules With Enhanced Performance by Nearly Double Compared to Existing Models]]></title><link>https://www.newswire.co.kr/newsRead.php?no=921432</link><description><![CDATA[SEOUL--(Korea Newswire)--Deargen, an artificial intelligence (AI)-based drug discovery and development biotech company, announced on April 9 that it presented study results on controlled molecule generator (CMG) technology at the ACM Conference on Health, Inference and Learning (ACM CHIL) 2021. The CMG technology can optimize multiple properties of molecules simultaneou...]]></description><pubDate>Tue, 13 Apr 2021 10:00:00 +0900</pubDate></item></channel></rss>